Document
false0000105770 0000105770 2019-10-24 2019-10-24


 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) – October 24, 2019
https://cdn.kscope.io/c44647840d1c14fe8d59cc19e7e15207-wstlogoq319.jpg
WEST PHARMACEUTICAL SERVICES, INC.
(Exact name of registrant as specified in its charter)
 
 
 
 
 
 
 
Pennsylvania
 
1-8036
 
23-1210010
(State or other jurisdiction
of incorporation)
 
(Commission File Number)
 
(IRS Employer
Identification No.)
 
 
 
 
 
 
 
530 Herman O. West Drive,
Exton,
PA
 
 
 
19341-0645
(Address of principal executive offices)
 
 
 
(Zip Code)
 Registrant’s telephone number, including area code: 610-594-2900
Not Applicable
(Former name or address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol
Name of each exchange on which registered
Common Stock, par value $0.25 per share
WST
New York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
 

1



Item 2.02 Results of Operations and Financial Condition.

On October 24, 2019, West Pharmaceutical Services, Inc. (the “Company”) issued a press release announcing its third-quarter 2019 financial results. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.

Item 7.01 Regulation FD Disclosure.

The information set forth in “Item 2.02 Results of Operations and Financial Condition,” including the exhibit referred to therein, is incorporated herein by reference.

A copy of the Company’s presentation materials used during the call will be available through the Investors link at the Company’s website, http://www.westpharma.com, and is also attached hereto as Exhibit 99.2 and incorporated herein by reference.

The information in this report (including the exhibits attached hereto) is being furnished pursuant to Item 2.02 and Item 7.01 and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (“Exchange Act”), or otherwise subject to the liabilities of that section, nor will it be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific referencing in such filing.

Item 9.01 Financial Statements and Exhibits.

(d)
Exhibit No.
Description
 
 99.1
West Pharmaceutical Services, Inc. Press Release, dated October 24, 2019.
 
 99.2
West Pharmaceutical Services, Inc. Presentation, dated October 24, 2019.
 
 104
The cover page from the Company’s Current Report on Form 8-K, dated October 24, 2019, formatted in Inline XBRL.




2






SIGNATURE


Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.



 
WEST PHARMACEUTICAL SERVICES, INC.
 
 
 
 
 
/s/ Bernard J. Birkett
 
Bernard J. Birkett
 
Senior Vice President, Chief Financial Officer and Treasurer
 
 
 
 
October 24, 2019
 




3







EXHIBIT INDEX


Exhibit No.
 
Description
99.1
 
99.2
 
104
 
The cover page from the Company’s Current Report on Form 8-K, dated October 24, 2019, formatted in Inline XBRL.


4
Exhibit


https://cdn.kscope.io/c44647840d1c14fe8d59cc19e7e15207-exh991logooct242019.jpg        
Exhibit 99.1

West Announces Third-Quarter 2019 Results
- Conference Call Scheduled for 9 a.m. EDT Today -

Exton, PA, October 24, 2019 – West Pharmaceutical Services, Inc. (NYSE: WST) today announced its financial results for the third-quarter 2019 and updated full-year 2019 financial guidance.
Third-Quarter 2019 Summary (comparisons to prior-year period)
Net sales of $456.1 million grew 5.7%; organic sales growth was 7.9%; sales from a recent acquisition contributed an additional 20 basis points of growth; currency translation reduced sales by 240 basis points.
Reported-diluted EPS of $0.75 increased 3%.
Adjusted-diluted EPS of $0.79 increased 4%.
Company is raising its full-year 2019 net sales guidance to a new range of between $1.815 billion and $1.825 billion.
Company is raising full-year 2019 adjusted-diluted EPS guidance to a new range of between $3.10 and $3.15.

“Adjusted-diluted EPS” and “organic sales growth” are Non-U.S. GAAP measurements. See discussion under the heading “Non-U.S. GAAP Financial Measures” in this release.

“Our third-quarter results demonstrate the forward momentum we have seen throughout 2019. In line with our expectations, we are seeing strong customer uptake of our high-value products (HVPs), especially in the Biologics market unit,” said Eric M. Green, President and Chief Executive Officer. “With the anticipated growing demand for our HVPs and positive trends in the marketplace, we expect our performance to continue to be strong for the remainder of the year and are raising our outlook for the full-year 2019.”

Mr. Green continued, “Earlier this month, we announced an increase in our minority equity stake to 49 percent in Daikyo Seiko, Ltd. The expansion of our long-standing relationship, on an exclusive basis, will ensure our continued success and strengthen our partnership with Daikyo.”

Proprietary Products Segment
Net sales grew by 6.2% to $345.2 million. Organic sales growth was 8.5%, with incremental sales from a recent acquisition contributing 30 basis points of Proprietary Products growth and currency translation decreasing sales by 260 basis points. HVPs (components and devices) represented 63% of segment sales and generated double-digit organic sales growth.

Our Biologics market unit had strong double-digit organic sales growth, led by customer purchases of NovaPure®, Daikyo® and Flurotec® components as well as products incorporating Daikyo’s Crystal Zenith® technology. Our Generics market unit posted mid-single digit organic





sales growth, led by sales of Daikyo components, products incorporating Crystal Zenith technology, self-injection platforms and Westar® RU. Our Pharma market unit saw a mid-single digit organic decline due to the impact of a previously reported voluntary recall of our Vial2Bag® product.

Contract-Manufactured Products Segment
Net sales grew by 4.2% to $111.1 million. Organic sales growth was 6.0% with currency translation decreasing sales by 180 basis points. Segment performance was led by sales of healthcare-related injection and diagnostic devices.

Financial Highlights (first nine months of 2019)
Operating cash flow was $260.8 million, an increase of 21%. Capital expenditures were $88.8 million, compared to $74.7 million over the same period last year. Free cash flow (operating cash flow minus capital expenditures) was $172.0 million, an increase of 22%.

The Company recorded $3.8 million of restructuring and related charges through the first nine months of 2019 from actions we have taken that are intended to streamline our manufacturing network. This restructuring plan is expected to be completed by the end of 2019 and result in $7.0 million of restructuring and related charges in 2019. Implemented in first-quarter 2018, the Company expects cumulative expenses over the plan period to be approximately $16.0 million. Once fully completed, the Company anticipates that the plan will provide annualized savings of approximately $14.0 million.

Full-Year 2019 Financial Guidance
The Company is raising its full-year 2019 net sales guidance to a new range of between $1.815 billion and $1.825 billion, compared to the prior guidance range of between $1.810 billion and $1.825 billion.
Organic sales growth is expected to be approximately 8%.
Net sales guidance includes a headwind of $54 million for the full-year 2019 based on current foreign exchange rates, compared to prior guidance of a full-year negative impact of $42 million.
The Company is raising full-year adjusted-diluted EPS guidance to a new range of between $3.10 and $3.15, compared to the prior guidance range of between $3.00 and $3.10.
This includes an estimated headwind of approximately $0.13 based on current foreign currency exchange rates, compared to prior guidance of a headwind of $0.10.
The acquisition of an incremental minority stake in Daikyo Seiko, Ltd., is not expected to have a material impact to West’s full-year 2019 financial outlook.

Third-Quarter 2019 Conference Call
The Company will host a conference call to discuss the results and business expectations at 9:00 a.m. Eastern Time today. To participate on the call please dial 877-930-8295 (U.S.) or 253-336-8738 (International). The conference ID is 9278868.

A live broadcast of the conference call will be available at the Company’s website, www.westpharma.com, in the “Investors” section. Management will refer to a slide presentation





during the call, which will be made available on the day of the call. To view the presentation, select “Presentations” in the “Investors” section of the Company’s website.

An online archive of the broadcast will be available at the website three hours after the live call and will be available through Thursday, October 31, 2019, by dialing 855-859-2056 (U.S.) or 404-537-3406 (International) and entering conference ID 9278868.












































Investor Contact:
Media Contact:
Quintin Lai
Emily Denney
Vice President, Investor Relations
Vice President, Communications
(610) 594-3318
(610) 594-3035
Quintin.Lai@westpharma.com
Emily.Denney@westpharma.com

Forward-Looking Statements
Certain forward-looking statements are included in this release. They use such words as “ensure,” “raising,” “seeing,” “growing,” “trends,” “continue,” “are intended,” “expected,” “expect,” “anticipates,” “includes,” “estimated,” and other similar terminology. These statements reflect management’s current expectations regarding future events and operating performance and speak only as of the date of this release. There is no certainty that actual results will be achieved in-line with current expectations. These forward-looking statements involve a number of risks and uncertainties. The following are some of the factors that could cause our actual results to differ materially from those expressed in or underlying our forward-looking statements: customers’ changing inventory requirements and manufacturing plans; customer decisions to move forward with our new products and product categories; average profitability, or mix, of the products we sell; dependence on third-party suppliers and partners; interruptions or weaknesses in our supply chain; increased raw material costs; fluctuations in currency exchange; the ability to meet development milestones with key customers; we cannot predict the time or expense required to address the issues created by, or impact on our financial results related to, the voluntary recall; and the voluntary recall and the related circumstances could subject us to claims or proceedings which may adversely impact our net sales and net income, as well as harm our reputation and customer relationships or distract management from operating our business. This list of important factors is not all inclusive. For a description of certain additional factors that could cause the Company’s future results to differ from those expressed in any such forward-looking statements, see Item 1A, entitled “Risk Factors,” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2018.

Except as required by law or regulation, we undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future events, or otherwise.


















Non-U.S. GAAP Financial Measures
For the purpose of aiding the comparison of our year-over-year results, we may refer to net sales and other financial results excluding the effects of changes in foreign currency exchange rates. Organic net sales exclude the impact from acquisitions and/or divestitures and translate the current-period reported sales of subsidiaries whose functional currency is other than the U.S. Dollar at the applicable foreign exchange rates in effect during the comparable prior-year period. We may also refer to financial results excluding the effects of unallocated items. The re-measured results excluding effects from currency translation, the impact from acquisitions and/or divestitures, and the effects of unallocated items are not in conformity with U.S. generally accepted accounting principles (U.S. GAAP) and should not be used as a substitute for the comparable U.S. GAAP financial measures. The non-U.S. GAAP financial measures are incorporated into our discussion and analysis as management uses them in evaluating our results of operations and believes that this information provides users a valuable insight into our overall performance and financial position. A reconciliation of these adjusted Non-U.S. GAAP financial measures to the comparable U.S. GAAP financial measures is included in the accompanying tables.






WEST PHARMACEUTICAL SERVICES, INC.
CONSOLIDATED STATEMENTS OF INCOME
(UNAUDITED)
(in millions, except per share data)


 
Three Months Ended
September 30,
 
Nine Months Ended
September 30,
 
2019
 
2018
 
2019
 
2018
Net sales
$
456.1

 
100
%
 
$
431.7

 
100
%
 
$
1,369.3

 
100
%
 
$
1,294.9

 
100
%
Cost of goods and services sold
308.3

 
68

 
296.1

 
69

 
916.8

 
67

 
882.7

 
68

Gross profit
147.8

 
32

 
135.6

 
31

 
452.5

 
33

 
412.2

 
32

Research and development
9.3

 
2

 
10.1

 
2

 
28.7

 
2

 
30.5

 
2

Selling, general and administrative expenses
64.8

 
14

 
64.9

 
15

 
203.7

 
15

 
203.2

 
16

Other expense (income), net
6.4

 
1

 
(0.2
)
 

 
1.6

 

 
4.0

 

Operating profit
67.3

 
15

 
60.8

 
14

 
218.5

 
16

 
174.5

 
14

Interest expense, net
1.1

 

 
1.5

 

 
3.9

 

 
4.7

 

Other nonoperating expense (income)
1.3

 
1

 
(1.8
)
 

 
0.2

 

 
(5.1
)
 

Income before income taxes
64.9

 
14

 
61.1

 
14

 
214.4

 
16

 
174.9

 
14

Income tax expense
10.9

 
2

 
8.0

 
2

 
42.5

 
3

 
26.5

 
2

Equity in net income of affiliated companies
(2.3
)
 

 
(2.1
)
 
1

 
(5.9
)
 

 
(6.5
)
 

Net income
$
56.3

 
12
%
 
$
55.2

 
13
%
 
$
177.8

 
13
%
 
$
154.9

 
12
%
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income per share:
 

 
 

 
 

 
 

 
 

 
 

 
 

 
 

Basic
$
0.76

 
 

 
$
0.75

 
 

 
$
2.40

 
 

 
$
2.10

 
 

Diluted
$
0.75

 
 

 
$
0.73

 
 

 
$
2.36

 
 

 
$
2.05

 
 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Average common shares outstanding
74.0

 
 

 
73.9

 
 

 
73.9

 
 

 
73.9

 
 

Average shares assuming dilution
75.5

 
 

 
75.7

 
 

 
75.3

 
 

 
75.4

 
 







WEST PHARMACEUTICAL SERVICES
REPORTING SEGMENT INFORMATION
(UNAUDITED)
(in millions)


 
Three Months Ended
September 30,
 
Nine Months Ended
September 30,
Net Sales:
2019
 
2018
 
2019
 
2018
Proprietary Products
$
345.2

 
$
325.2

 
$
1,045.9

 
$
997.4

Contract-Manufactured Products
111.1

 
106.7

 
323.6

 
297.7

Eliminations
(0.2
)
 
(0.2
)
 
(0.2
)
 
(0.2
)
Consolidated Total
$
456.1

 
$
431.7

 
$
1,369.3

 
$
1,294.9

 
 
 
 
 
 
 
 
Gross Profit:
 
 
 
 
 
 
 
Proprietary Products
$
131.8

 
$
120.4

 
$
406.3

 
$
370.4

Contract-Manufactured Products
16.0

 
15.2

 
46.2

 
41.8

Gross Profit
$
147.8

 
$
135.6

 
$
452.5

 
$
412.2

Gross Profit Margin
32.4
%
 
31.4
%
 
33.0
%
 
31.8
%
 
 
 
 
 
 
 
 
Operating Profit (Loss):
 

 
 

 
 

 
 

Proprietary Products
$
72.9

 
$
68.2

 
$
238.7

 
$
202.7

Contract-Manufactured Products
11.6

 
11.2

 
33.5

 
29.7

U.S. pension expense

 
(2.3
)
 

 
(7.0
)
Stock-based compensation expense
(5.4
)
 
(5.3
)
 
(18.8
)
 
(14.7
)
General corporate costs
(9.0
)
 
(8.7
)
 
(30.1
)
 
(28.4
)
Adjusted Operating Profit
$
70.1

 
$
63.1

 
$
223.3

 
$
182.3

Adjusted Operating Profit Margin
15.4
%
 
14.6
%
 
16.3
%
 
14.1
%
 
 
 
 
 
 
 
 
Restructuring and related charges
(1.8
)
 
(1.2
)
 
(3.8
)
 
(6.7
)
Argentina currency devaluation
(1.0
)
 
(1.1
)
 
(1.0
)
 
(1.1
)
Reported Operating Profit
$
67.3

 
$
60.8

 
$
218.5

 
$
174.5

Reported Operating Profit Margin
14.8
%
 
14.1
%
 
16.0
%
 
13.5
%







WEST PHARMACEUTICAL SERVICES
RECONCILIATION OF NON-U.S. GAAP MEASURES (UNAUDITED)
Please refer to “Non-U.S. GAAP Financial Measures” for more information
(in millions, except per share data)


Reconciliation of Reported and Adjusted Operating Profit, Net Income and Diluted EPS

Three Months Ended September 30, 2019
Operating
profit
Income tax
expense
Net
income
Diluted
EPS
Reported (U.S. GAAP)
$
67.3

$
10.9

$
56.3

$
0.75

Restructuring and related charges (1)
1.8

0.4

1.4

0.01

Pension settlement (2)

0.6

2.1

0.03

Argentina currency devaluation (3)
1.0

0.3

0.7

0.01

Tax law changes (4)

1.0

(1.0
)
(0.01
)
Adjusted (Non-U.S. GAAP)
$
70.1

$
13.2

$
59.5

$
0.79


Nine Months Ended September 30, 2019
Operating
profit
Income
tax
expense
Net
income
Diluted
EPS
Reported (U.S. GAAP)
$
218.5

$
42.5

$
177.8

$
2.36

Restructuring and related charges (1)
3.8

0.9

2.9

0.03

Pension settlement (2)

0.6

2.1

0.03

Argentina currency devaluation (3)
1.0

0.3

0.7

0.01

Tax law changes (4)

1.0

(1.0
)
(0.01
)
Adjusted (Non-U.S. GAAP)
$
223.3

$
45.3

$
182.5

$
2.42


Three Months Ended September 30, 2018
Operating
profit
Income
tax
expense
Net
income
Diluted
EPS
Reported (U.S. GAAP)
$
60.8

$
8.0

$
55.2

$
0.73

Restructuring and related charges (1)
1.2

0.3

0.9

0.01

Argentina currency devaluation (3)
1.1


1.1

0.02

Tax law changes (4)

(0.4
)
0.4


Adjusted (Non-U.S. GAAP)
$
63.1

$
7.9

$
57.6

$
0.76







Nine Months Ended September 30, 2018
Operating
profit
Income
tax
expense
Net
income
Diluted
EPS
Reported (U.S. GAAP)
$
174.5

$
26.5

$
154.9

$
2.05

Restructuring and related charges (1)
6.7

1.5

5.2

0.07

Argentina currency devaluation (3)
1.1


1.1

0.02

Tax law changes (4)

4.1

(4.1
)
(0.06
)
Adjusted (Non-U.S. GAAP)
$
182.3

$
32.1

$
157.1

$
2.08







(1)
During the three and nine months ended September 30, 2019, the Company recorded $1.8 million and $3.8 million, respectively, in restructuring and related charges. During the three and nine months ended September 30, 2018, the Company recorded $1.2 million and $6.7 million, respectively, in restructuring and related charges. Full-year 2019 expected restructuring and related charges to complete its current plan remain unchanged at $7.0 million. Once fully completed, the Company expects that the plan will provide annualized savings of approximately $14.0 million.

(2)
During the three and nine months ended September 30, 2019, the Company recorded a pension settlement charge of $2.7 million within other nonoperating expense (income), as it determined that normal-course lump-sum payments for each of its U.S. qualified and non-qualified defined benefit pension plans exceeded the threshold for settlement accounting under U.S. GAAP for the year.

(3)
During the three and nine months ended September 30, 2019, the Company recorded a charge of $1.0 million related to the continued devaluation of Argentina’s currency. During the three and nine months ended September 30, 2018, the Company recorded a charge of $1.1 million related to the classification of Argentina’s economy as highly inflationary under U.S. GAAP as of July 1, 2018.

(4)
During the three and nine months ended September 30, 2019, the Company recorded a tax benefit of $1.0 million due to the impact of federal law changes enacted during the quarter. During the three and nine months ended September 30, 2018, the Company recorded a net tax charge of $0.4 million and a net tax benefit of $4.1 million, respectively, for the estimated impact of the Tax Cuts and Jobs Act.

















WEST PHARMACEUTICAL SERVICES
RECONCILIATION OF NON-U.S. GAAP FINANCIAL MEASURES (UNAUDITED)
Please refer to “Non-U.S. GAAP Financial Measures” for more information
(in millions, except per share data)


Reconciliation of Net Sales to Organic Net Sales (5) 

Three Months Ended September 30, 2019
Proprietary
CM
Eliminations
Total
Reported net sales (U.S. GAAP)
$
345.2

$
111.1

$
(0.2
)
$
456.1

Effect of acquisitions and/or divestitures
(1.0
)


(1.0
)
Effect of changes in currency translation rates
8.6

2.0


10.6

Organic net sales (Non-U.S. GAAP) (5)
$
352.8

$
113.1

$
(0.2
)
$
465.7


Nine Months Ended September 30, 2019
Proprietary
CM
Eliminations
Total
Reported net sales (U.S. GAAP)
$
1,045.9

$
323.6

$
(0.2
)
$
1,369.3

Effect of acquisitions and/or divestitures
(2.0
)


(2.0
)
Effect of changes in currency translation rates
37.6

7.7


45.3

Organic net sales (Non-U.S. GAAP) (5)
$
1,081.5

$
331.3

$
(0.2
)
$
1,412.6

 
 
(5)
Organic net sales exclude the impact from acquisitions and/or divestitures and translates the current-period reported sales of subsidiaries whose functional currency is other than the U.S. Dollar at the applicable foreign exchange rates in effect during the comparable prior-year period.


























WEST PHARMACEUTICAL SERVICES
RECONCILIATION OF NON-U.S. GAAP FINANCIAL MEASURES (UNAUDITED)
Please refer to “Non-U.S. GAAP Financial Measures” for more information
(in millions, except per share data)


Reconciliation of Reported-Diluted EPS Guidance to Adjusted-Diluted EPS Guidance


 
2018 Actual
2019 Guidance
% Change
Reported-diluted EPS (U.S. GAAP)
$2.74
$2.99 to $3.04
9.1% to 10.9%
Restructuring and related charges
0.08
0.07
 
Pension settlement
0.04
 
Argentina currency devaluation
0.02
0.01
 
Tax law changes
(0.03)
(0.01)
 
Adjusted-diluted EPS (Non-U.S. GAAP) (6)
$2.81
$3.10 to $3.15
10.3% to 12.1%


Notes:

See “Full-Year 2019 Financial Guidance” and “Non-U.S. GAAP Financial Measures” in today’s press release for additional information regarding adjusted-diluted EPS.
 
(6)
In 2018, tax benefits associated with stock-based compensation increased adjusted-diluted EPS by $0.19. We have opted not to forecast 2019 tax benefits from stock-based compensation in upcoming quarters, as they are out of the Company’s control. Instead, we recognize the benefits as they occur. In the third-quarter 2019 and first-nine months of 2019, tax benefits associated with stock-based compensation increased adjusted-diluted EPS by $0.05 and $0.12, respectively. Any future tax benefits associated with stock-based compensation that we receive in 2019 would provide a positive adjustment to our full-year EPS guidance.









WEST PHARMACEUTICAL SERVICES
CASH FLOW ITEMS
(UNAUDITED)
(in millions)

 
Nine Months Ended September 30,
 
2019
 
2018
Depreciation and amortization
$
77.1

 
$
78.1

Operating cash flow
$
260.8

 
$
215.4

Capital expenditures
$
88.8

 
$
74.7





WEST PHARMACEUTICAL SERVICES
FINANCIAL CONDITION
(UNAUDITED)
(in millions)

 
As of
September 30, 2019
 
As of
December 31, 2018
Cash and cash equivalents
$
396.0

 
$
337.4

Accounts receivable, net
$
316.1

 
$
288.2

Inventories
$
230.4

 
$
214.5

Accounts payable
$
145.3

 
$
130.4

Debt
$
195.1

 
$
196.1

Equity
$
1,487.6

 
$
1,396.3

Working capital
$
669.1

 
$
610.7




Trademark Notices

Trademarks and registered trademarks are the property of West Pharmaceutical Services, Inc., in the United States and other jurisdictions, unless noted otherwise.
Daikyo Crystal Zenith® and Daikyo CZ® are registered trademarks of Daikyo Seiko, Ltd. Daikyo Crystal Zenith technologies are licensed from Daikyo Seiko, Ltd.

 



q32019wstpresentation
West Pharmaceutical Services, Inc. Third-Quarter 2019 Analyst Conference Call 9 a.m. Eastern Time, October 24, 2019 ▪ A webcast of today’s call can be accessed in the “Investors” section of the Company’s website: www.westpharma.com Speakers: ▪ To participate on the call, please dial: Eric M. Green − 877-930-8295 (U.S.) President and Chief Executive Officer − 253-336-8738 (International) − The conference ID is 9278868 Bernard J. Birkett Senior Vice President, Chief Financial Officer ▪ An online archive of the broadcast will be available at the website three and Treasurer hours after the live call and will be available through Thursday, October 31, 2019, by dialing: − 855-859-2056 (U.S.) − 404-537-3406 (International) − The conference ID is 9278868 These presentation materials are intended to accompany today’s press release announcing the Company’s results for the third- quarter 2019 and management’s discussion of those results during today’s conference call. 1 WST Q3 2019 Earnings


 
Safe Harbor Statement Cautionary Statement Under the Private Securities Litigation Reform Act of 1995 This presentation and any accompanying management commentary contain “forward-looking statements” as that term is defined in the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about product development and operational performance. Each of these statements is based on preliminary information, and actual results could differ from any preliminary estimates. We caution investors that the risk factors listed under “Cautionary Statement” in our press releases, as well as those set forth under the caption "Risk Factors" in our most recent Annual Report on Form 10-K as filed with the Securities and Exchange Commission and as revised or supplemented by our quarterly reports on Form 10-Q, could cause our actual results to differ materially from those estimated or predicted in the forward-looking statements. You should evaluate any statement in light of these important factors. Except as required by law or regulation, we undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future events, or otherwise. Non-U.S. GAAP Financial Measures Certain financial measures included in these presentation materials, or which may be referred to in management’s discussion of the Company’s results and outlook, have not been calculated in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”), and therefore are referred to as non-U.S. GAAP financial measures. Non-U.S. GAAP financial measures should not be considered in isolation or as an alternative to such measures determined in accordance with U.S. GAAP. Please refer to “Reconciliation of Non-U.S. GAAP Financial Measures” at the end of these materials for more information. Trademarks Registered trademarks used in this report are the property of West Pharmaceutical Services, Inc. or its subsidiaries, in the United States and other jurisdictions, unless noted otherwise. Daikyo Crystal Zenith® and Daikyo® are registered trademarks of Daikyo Seiko, Ltd. 2 WST Q3 2019 Earnings


 
Third-Quarter 2019 Earnings Highlights • Net sales of $456.1 million grew 5.7%, organic sales growth was 7.9% • Reported-diluted EPS of $0.75 increased 3% • Adjusted-diluted EPS of $0.79 increased 4% (1) • Company raised full-year 2019 net sales guidance to a new range of between $1.815 billion and $1.825 billion, compared to the prior guidance range of between $1.810 billion and $1.825 billion • Company raised full-year 2019 adjusted-diluted EPS guidance to a new range of between $3.10 and $3.15, compared to the prior guidance range of between $3.00 and $3.10 (1) (1) Please refer to “Notes to Non-U.S. GAAP Financial Measures” on slides 11-15, and “Non-U.S. GAAP Financial Measures” in today’s press release, for additional information regarding adjusted-diluted EPS. 3 WST Q3 2019 Earnings


 
Organic Sales Growth Q3 2019 Overall Organic Proprietary Products organic sales growth of 8.5%, led by sales of 7.9% Sales Growth high-value products, which grew double digits Sales led by high-value products, including NovaPure®, Daikyo® and ® BIOLOGICS Biologics DD Flurotec components as well as products incorporating Daikyo’s Crystal Zenith® technology Sales led by sales of Daikyo components, products incorporating Generics MSD GENERICS Crystal Zenith technology, self-injection platforms and Westar® RU Sales decline due to the impact of a previously-reported voluntary Pharma (MSD) PHARMA recall of our Vial2Bag® product Contract Organic sales growth of 6.0%, led by sales of healthcare-related CONTRACT MSD MFG Manufacturing injection and diagnostic devices Abbreviations: LSD – low-single digit; MSD – mid-single digit; HSD – high-single digit; DD – double digit 4 WST Q3 2019 Earnings


 
High-Value Product Expansion Opportunities 5 WST Q3 2019 Earnings


 
Third-Quarter 2019 Summary Results ($ millions, except earnings-per-share (EPS) data) Three Months Ended September 30, 2019 2018 Reported Net Sales $456.1 $431.7 Gross Profit Margin 32.4% 31.4% Reported Operating Profit $67.3 $60.8 Adjusted Operating Profit $70.1 $63.1 Reported-Diluted EPS $0.75 $0.73 Adjusted-Diluted EPS(1) $0.79 $0.76 (1) “Adjusted-diluted EPS” is a Non-U.S. GAAP financial measure. See slides 11-15 and the discussion under the heading “Non-U.S. GAAP Financial Measures” in today’s press release for an explanation and reconciliation of this item. Except as noted, statements in these slides concerning comparative sales are measured on a constant-currency basis. 6 WST Q3 2019 Earnings


 
Change in Consolidated Net Sales Third-quarter 2018 to 2019 ($ millions) 7 WST Q3 2019 Earnings


 
Gross Profit Update ($ millions) Three Months Ended September 30, 2019 2018 Proprietary Products Gross Profit $131.8 $120.4 Proprietary Products Gross Profit Margin 38.2% 37.0% Contract-Manufactured Products Gross Profit $16.0 $15.2 Contract-Manufactured Products Gross Profit Margin 14.4% 14.3% Consolidated Gross Profit $147.8 $135.6 Consolidated Gross Profit Margin 32.4% 31.4% 8 WST Q3 2019 Earnings


 
Cash Flow and Balance Sheet Metrics ($ millions) Cash Flow Items Financial Condition YTD YTD September 30, December 31, Q319 Q318 2019 2018 Depreciation and Amortization $77.1 $78.1 Cash and Cash Equivalents $396.0 $337.4 Operating Cash Flow $260.8 $215.4 Debt $195.1 $196.1 Capital Expenditures $88.8 $74.7 Equity $1,487.6 $1,396.3 Working Capital $669.1 $610.7 9 WST Q3 2019 Earnings


 
2019 Full-Year Guidance 2019 Full-Year Guidance(1,2) Consolidated Net Sales $1.815 - $1.825 billion Adjusted-Diluted EPS $3.10 - $3.15 (1) Please refer to “Notes to Non-U.S. GAAP Financial Measures” on slides 11-15, and “Non-U.S. GAAP Financial Measures” in today’s press release, for additional information regarding adjusted-diluted EPS. (2) Guidance excludes possible cost and benefits from the announced 2018 Global Operations restructuring plan. It also does not include potential future tax benefits from stock- based compensation. 10 WST Q3 2019 Earnings


 
Notes to Non-U.S. GAAP Financial Measures For additional details, please see today’s press release & Safe Harbor Statement ▪ For the purpose of aiding the comparison of our year-over-year results, we may refer to net sales and other financial results excluding the effects of changes in foreign currency exchange rates. ▪ Organic net sales exclude the impact from acquisitions and/or divestitures and translate the current-period reported sales of subsidiaries whose functional currency is other than the U.S. Dollar at the applicable foreign exchange rates in effect during the comparable prior-year period. ▪ We may also refer to financial results excluding the effects of unallocated items. ▪ The re-measured results excluding effects from currency translation, the impact from acquisitions and/or divestitures, and the effects of unallocated items are not in conformity with U.S. GAAP and should not be used as a substitute for the comparable U.S. GAAP financial measures. ▪ The non-U.S. GAAP financial measures are incorporated into our discussion and analysis as management uses them in evaluating our results of operations and believes that this information provides users a valuable insight into our overall performance and financial position. ▪ A reconciliation of these adjusted Non-U.S. GAAP financial measures to the comparable U.S. GAAP financial measures is included in the accompanying tables. 11 WST Q3 2019 Earnings


 
Notes to Non-U.S. GAAP Financial Measures RECONCILIATION OF NON-U.S. GAAP FINANCIAL MEASURES (UNAUDITED) See “Notes to Non-U.S. GAAP Financial Measures” (Slides 11-15), “Cautionary Statement” (Slide 2) and today’s press release for an explanation and reconciliation of these items. Reconciliation of Reported and Adjusted Operating Profit, Net Income and Diluted EPS ($ millions, except EPS data) Operating Income tax Net Diluted Three months ended September 30, 2019 profit expense income EPS Reported (U.S. GAAP) $67.3 $10.9 $56.3 $0.75 Restructuring and related charges 1.8 0.4 1.4 0.01 Pension settlement - 0.6 2.1 0.03 Argentina currency devaluation 1.0 0.3 0.7 0.01 Tax law changes - 1.0 (1.0) (0.01) Adjusted (Non-U.S. GAAP) $70.1 $13.2 $59.5 $0.79 Operating Income tax Net Diluted Nine months ended September 30, 2019 profit expense income EPS Reported (U.S. GAAP) $218.5 $42.5 $177.8 $2.36 Restructuring and related charges 3.8 0.9 2.9 0.03 Pension settlement - 0.6 2.1 0.03 Argentina currency devaluation 1.0 0.3 0.7 0.01 Tax law changes - 1.0 (1.0) (0.01) Adjusted (Non-U.S. GAAP) $223.3 $45.3 $182.5 $2.42 12 WST Q3 2019 Earnings


 
Notes to Non-U.S. GAAP Financial Measures RECONCILIATION OF NON-U.S. GAAP FINANCIAL MEASURES (UNAUDITED) See “Notes to Non-U.S. GAAP Financial Measures” (Slides 11-15), “Cautionary Statement” (Slide 2) and today’s press release for an explanation and reconciliation of these items. Reconciliation of Reported and Adjusted Operating Profit, Net Income and Diluted EPS ($ millions, except EPS data) Operating Income tax Net Diluted Three months ended September 30, 2018 profit expense income EPS Reported (U.S. GAAP) $60.8 $8.0 $55.2 $0.73 Restructuring and related charges 1.2 0.3 0.9 0.01 Argentina currency devaluation 1.1 - 1.1 0.02 Tax law changes - (0.4) 0.4 - Adjusted (Non-U.S. GAAP) $63.1 $7.9 $57.6 $0.76 Operating Income tax Net Diluted Nine months ended September 30, 2018 profit expense income EPS Reported (U.S. GAAP) $174.5 $26.5 $154.9 $2.05 Restructuring and related charges 6.7 1.5 5.2 0.07 Argentina currency devaluation 1.1 - 1.1 0.02 Tax law changes - 4.1 (4.1) (0.06) Adjusted (Non-U.S. GAAP) $182.3 $32.1 $157.1 $2.08 13 WST Q3 2019 Earnings


 
Notes to Non-U.S. GAAP Financial Measures RECONCILIATION OF NON-U.S. GAAP FINANCIAL MEASURES (UNAUDITED) See “Notes to Non-U.S. GAAP Financial Measures” (Slides 11-15), “Cautionary Statement” (Slide 2) and today’s press release for an explanation and reconciliation of these items. Reconciliation of Net Sales to Organic Net Sales (1) ($ millions) Three months ended September 30, 2019 Proprietary CM Eliminations Total Reported net sales (U.S. GAAP) $345.2 $111.1 $(0.2) $456.1 Effect of acquisitions and/or divestitures (1.0) - - (1.0) Effect of changes in currency translation rates 8.6 2.0 - 10.6 Organic net sales (Non-U.S. GAAP) (1) $352.8 $113.1 $(0.2) $465.7 Nine months ended September 30, 2019 Proprietary CM Eliminations Total Reported net sales (U.S. GAAP) $1,045.9 $323.6 $(0.2) $1,369.3 Effect of acquisitions and/or divestitures (2.0) - - (2.0) Effect of changes in currency translation rates 37.6 7.7 - 45.3 Organic net sales (Non-U.S. GAAP) (1) $1,081.5 $331.3 $(0.2) $1,412.6 (1) Organic net sales exclude the impact from acquisitions and/or divestitures and translate the current-period reported sales of subsidiaries whose functional currency is other than the U.S. Dollar at the applicable foreign exchange rates in effect during the comparable prior-year period. 14 WST Q3 2019 Earnings


 
Notes to Non-U.S. GAAP Financial Measures RECONCILIATION OF NON-U.S. GAAP FINANCIAL MEASURES (UNAUDITED) See “Notes to Non-U.S. GAAP Financial Measures” (Slides 11-15), “Cautionary Statement” (Slide 2) and today’s press release for an explanation and reconciliation of these items. Reconciliation of Reported-Diluted EPS Guidance to Adjusted-Diluted EPS Guidance 2018 Actual 2019 Guidance % Change Reported-diluted EPS (U.S. GAAP) $2.74 $2.99 to $3.04 9.1% to 10.9% Restructuring and related charges 0.08 0.07 Pension settlement - 0.04 Argentina currency devaluation 0.02 0.01 Tax law changes (0.03) (0.01) Adjusted-diluted EPS (Non-U.S. GAAP)(1) $2.81 $3.10 to $3.15 10.3% to 12.1% (1) See “Full-Year 2019 Financial Guidance” and “Non-U.S. GAAP Financial Measures” in today’s press release for additional information regarding adjusted-diluted EPS. In 2018, tax benefits associated with stock-based compensation increased adjusted-diluted EPS by $0.19. We have opted not to forecast 2019 tax benefits from stock-based compensation in upcoming quarters, as they are out of the Company’s control. Instead, we recognize the benefits as they occur. In the third-quarter 2019 and first-nine months of 2019, tax benefits associated with stock-based compensation increased adjusted-diluted EPS by $0.05 and $0.12, respectively. Any future tax benefits associated with stock-based compensation that we receive in 2019 would provide a positive adjustment to our full-year EPS guidance. 15 WST Q3 2019 Earnings